Key result
In patients with severe hypertriglyceridemia without pancreatitis, combination therapy with insulin, heparin, and fenofibrate significantly reduced median triglyceride levels to 437 mg/dL by day 6.
Why the study?
The safety and benefits of combining heparin, insulin, and fenofibrate for severe hypertriglyceridemia have not been accurately weighed due to limited sample sizes in existing studies.
Does the combination of insulin, heparin, and fenofibrate reduce triglyceride levels in patients with severe hypertriglyceridemia?
Observational (n=42)
Yes
Does the combination of insulin, heparin, and fenofibrate reduce triglyceride levels in patients with severe hypertriglyceridemia?
Combination therapy with insulin, heparin, and fenofibrate safely and rapidly reduces triglyceride levels in patients with severe hypertriglyceridemia.
May support insulin-heparin-fenofibrate for rapid TG reduction in severe hypertriglyceridemia; hypothesis-generating, needs RCTs before practice change.
CONTEXT: Severe hypertriglyceridemia (SH), which calls for a triglyceride (TG) level above 1000 mg/dL, remains an important health issue. While some data exist to offer combination of heparin, insulin and fenofibrate as a reasonable treatment option, safety and benefits of this therapy have not been accurately weighted, largely due to the limited sample size of the relevant studies. AIM: Assess the efficacy and safety of the heparin, insulin and fenofibrate combination in the treatment of patients with SH. PATIENTS - METHODS: days of the treatment. Treatment dosage, duration, response and side effects were assessed. Patients with hypertriglyceridemia presenting with acute pancreatitis were treated additionally with lipid apheresis. RESULTS: day of the treatment (p<0.0001, Friedman test). Potential toxicities related to insulin, heparin and fenofibrate combination treatment including hypoglycemia, hemorrhage, rise in creatine kinase levels, hepato - and nephrotoxicity were not observed. CONCLUSION: In this trial involving patients with SH, our data suggest that insulin, heparin and fenofibrate combination therapy was safe and effective.
No takes yet. Share an insight, caveat, or question.
A 2019 study conducted an observational in Severe hypertriglyceridemia (n=42). Insulin, heparin, and fenofibrate combination was evaluated on Median triglyceride levels on the 6th day of treatment in patients without pancreatitis (p=<0.0001). In patients with severe hypertriglyceridemia without pancreatitis, combination therapy with insulin, heparin, and fenofibrate significantly reduced median triglyceride levels to 437 mg/dL by day 6.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: